NO985667L - FremgangsmÕte for fremstilling av medikamentkompleks - Google Patents

FremgangsmÕte for fremstilling av medikamentkompleks

Info

Publication number
NO985667L
NO985667L NO985667A NO985667A NO985667L NO 985667 L NO985667 L NO 985667L NO 985667 A NO985667 A NO 985667A NO 985667 A NO985667 A NO 985667A NO 985667 L NO985667 L NO 985667L
Authority
NO
Norway
Prior art keywords
spacer
drug compound
bound
carboxyl groups
polysaccharide derivative
Prior art date
Application number
NO985667A
Other languages
English (en)
Other versions
NO323626B1 (no
NO985667D0 (no
Inventor
Kazuhiro Inoue
Hiroshi Susaki
Masahiro Ikeda
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of NO985667D0 publication Critical patent/NO985667D0/no
Publication of NO985667L publication Critical patent/NO985667L/no
Publication of NO323626B1 publication Critical patent/NO323626B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO19985667A 1996-06-06 1998-12-04 Fremgangsmate for fremstilling av et medikamentkompleks NO323626B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14452296 1996-06-06
PCT/JP1997/001915 WO1997046261A1 (en) 1996-06-06 1997-06-05 Process for producing drug complexes

Publications (3)

Publication Number Publication Date
NO985667D0 NO985667D0 (no) 1998-12-04
NO985667L true NO985667L (no) 1999-02-04
NO323626B1 NO323626B1 (no) 2007-06-18

Family

ID=15364300

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19985667A NO323626B1 (no) 1996-06-06 1998-12-04 Fremgangsmate for fremstilling av et medikamentkompleks

Country Status (16)

Country Link
US (1) US6291671B1 (no)
EP (1) EP0955064B1 (no)
JP (1) JP4137184B2 (no)
CN (1) CN1227034C (no)
AT (1) ATE273716T1 (no)
AU (1) AU723442B2 (no)
CA (1) CA2257233A1 (no)
DE (1) DE69730352T2 (no)
DK (1) DK0955064T3 (no)
EA (1) EA001897B1 (no)
ES (1) ES2229355T3 (no)
ID (1) ID17243A (no)
NO (1) NO323626B1 (no)
PT (1) PT955064E (no)
TW (1) TW409058B (no)
WO (1) WO1997046261A1 (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CA2333321A1 (en) * 1998-05-22 1999-12-02 Daiichi Pharmaceutical Co., Ltd. Drug complex
MXPA02012791A (es) * 2000-06-29 2003-12-11 Daiichi Seiyaku Co Compuestos dds y metodo para prepararlo.
US20040234497A1 (en) * 2001-05-04 2004-11-25 Yi Luo Hyaluronic acid containing bioconjugates:targeted delivery of anti-cancer drugs to cancer cells
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US7691830B2 (en) * 2005-02-17 2010-04-06 Clive Elson Method and composition for treatment of a mucosal tissue disorder
CA2912012C (en) 2005-05-05 2018-05-29 Sensient Flavors Inc. Production of beta-glucans and mannans
WO2007004675A1 (ja) * 2005-07-06 2007-01-11 Seikagaku Corporation 薬剤導入光架橋ヒアルロン酸誘導体ゲル
ITPD20050242A1 (it) 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
CN1973902B (zh) * 2006-12-12 2010-11-10 东北师范大学 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
WO2011150022A2 (en) 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
SI3342785T1 (sl) 2012-10-11 2020-02-28 Daiichi Sankyo Company, Limited Povezovalci za konjugate protitelesa in zdravila
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート
ES2749746T3 (es) 2013-04-10 2020-03-23 Syndevrx Inc Inhibidores de fumagilol metap2 modificados o conjugados con polímeros para uso en el tratamiento de la obesidad
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
WO2015098099A1 (ja) 2013-12-25 2015-07-02 第一三共株式会社 抗trop2抗体-薬物コンジュゲート
RS62618B1 (sr) 2014-01-31 2021-12-31 Daiichi Sankyo Co Ltd Anti-her2 antitelo-lek konjugat
EP3129063B1 (en) 2014-04-10 2021-01-27 Daiichi Sankyo Company, Limited Anti-her3 antibody-drug conjugate
WO2015155976A1 (ja) 2014-04-10 2015-10-15 第一三共株式会社 抗her2抗体-薬物コンジュゲート
BR112017027690A2 (pt) 2015-06-29 2018-10-09 Daiichi Sankyo Co Ltd “método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
MX2018006904A (es) 2015-12-10 2018-08-24 Syndevrx Inc Derivados de fumagilol y polimorfos de los mismos.
CN114225045A (zh) 2016-01-11 2022-03-25 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
IL268102B1 (en) 2017-01-17 2024-08-01 Daiichi Sankyo Co Ltd Anti-GPR 20 antibody and anti-GPR 20 antibody-drug conjugate
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
BR112020003646A2 (pt) 2017-08-31 2020-09-01 Daiichi Sankyo Company, Limited cristais, métodos para produção de cristais e de um conjugado anticorpo-fármaco, e, sal.
SG11202001514XA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Novel method for producing antibody-drug conjugate
SI3794042T1 (sl) 2018-05-18 2024-07-31 Daiichi Sankyo Co., Ltd. Konjugat protitelesa anti-MUC1-exatecan in citotoksično sredstvo
EP3870231A1 (en) 2018-10-26 2021-09-01 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
EP3996749A1 (en) 2019-07-10 2022-05-18 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2093697A (en) * 1980-09-03 1982-09-08 Kyosei Pharmaceutical Co Ltd Agent for alimentary canal
JPS5746920A (en) * 1980-09-03 1982-03-17 Kyosei Seiyaku Kk Drug for digestive tract
JPS59220197A (ja) * 1983-05-30 1984-12-11 Snow Brand Milk Prod Co Ltd 新規な含窒素多糖体およびその製造方法
JP2604930B2 (ja) * 1990-12-14 1997-04-30 株式会社ディ・ディ・エス研究所 ヒアルロン酸およびコンドロイチン誘導体
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
DE69225542T2 (de) 1991-02-21 1998-09-10 Drug Delivery System Inst Ltd Carboxymethylmannoglukan und derivate davon
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
ES2149867T3 (es) 1993-02-26 2000-11-16 Drug Delivery System Inst Ltd Derivados de polisacaridos y soportes para farmacos.
JPH0784481A (ja) 1993-06-26 1995-03-31 Ricoh Co Ltd 画像形成装置
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts

Also Published As

Publication number Publication date
CN1227500A (zh) 1999-09-01
CN1227034C (zh) 2005-11-16
DE69730352D1 (de) 2004-09-23
ATE273716T1 (de) 2004-09-15
NO323626B1 (no) 2007-06-18
ID17243A (id) 1997-12-11
EP0955064A1 (en) 1999-11-10
NO985667D0 (no) 1998-12-04
TW409058B (en) 2000-10-21
AU723442B2 (en) 2000-08-24
DE69730352T2 (de) 2005-09-08
EP0955064B1 (en) 2004-08-18
ES2229355T3 (es) 2005-04-16
JP4137184B2 (ja) 2008-08-20
AU2978897A (en) 1998-01-05
US6291671B1 (en) 2001-09-18
DK0955064T3 (da) 2004-12-06
CA2257233A1 (en) 1997-12-11
EA001897B1 (ru) 2001-10-22
EA199900002A1 (ru) 1999-08-26
EP0955064A4 (en) 2000-12-06
PT955064E (pt) 2004-10-29
WO1997046261A1 (en) 1997-12-11

Similar Documents

Publication Publication Date Title
NO985667L (no) FremgangsmÕte for fremstilling av medikamentkompleks
EA199900004A1 (ru) Лекарственный комплекс
CA2135138A1 (en) Method for producing formic acid or its derivatives
DK1053355T3 (da) PNA- og DNA-konjugater og metoder til fremstilling heraf
ATE110110T1 (de) Verfahren zum immobilisieren von proteinen, peptiden, coenzymen od.dgl. an einem träger.
CA2399187A1 (en) Kahalalide compounds
AU587827B2 (en) Oligopeptide derivatives, their production and their use as surfactantes kind to the skin
EA199800811A1 (ru) Способ получения нитробифенилов
MX9303631A (es) Compuestos de cerio (iv), su preparacion y empleo.
BG50164A3 (en) Method for preparing of amicacine
MY131384A (en) Novel 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
PT83837A (de) Verfahren zur herstellung von peptiden unter der verwendung von perchloraten
BR9301627A (pt) Processo para preparar cefalosporinas
EP0344791A3 (en) Process for the enzymatic resolution of the optical isomers of racemic ester derivatives of 3-mercapto-2-alkyl-propionic acid
RU93031156A (ru) Способ получения плазмид, кодирующих химерный белок с последовательностью соматостатина, штамм бактерий escherichia coli - продуцент этого белка, белок, полученный в этом штамме, содержащий фрагмент ацетилтрансферазы, спейсер и иммуногенный соматостатин
AU629008B2 (en) Compounds from biopolymrs and effector substances which are linked via optically active amino acid derivatives, processes for the preparation thereof and the use thereof
GR3002989T3 (en) Process for the production of n-acylated mercapto-alpha-amino acids
FI885638A (fi) Menetelmä lääkeaineina käyttökelpoisten griseoliinihappomonoesterijohdannaisten valmistamiseksi
EP0226132A3 (de) Dipeptide mit C-terminalem Phosphinothricin, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
BR8901324A (pt) Processos para a preparacao de um metil ester de alfa-l-aspartil-l-fenilalanina com n protegido,para a preparacao de um anidrido aspartico com n protegido e para a preparacao de anidrido n-benziloxicarbonil-l-aspartico
GB1359451A (en) Process for producing desacetoyxycephalosporin derivatives
TH26735A (th) กระบวนการสำหรับการลดคอนเทนต์ผลพลอยได้ของคาร์เบนเดซิม
AT387380B (de) Verfahren und zwischenprodukte fuer n-(s-3alkyl-heptanoyl)-d-gamma-glutamyl-glycyl-dalanin
RU93004674A (ru) Способ получения цефалоспоринов
DE68905188D1 (de) Fermentationsprozess fuer carboxylsaeuren.